Short Interest in AlloVir, Inc. (NASDAQ:ALVR) Declines By 12.0%

AlloVir, Inc. (NASDAQ:ALVR) saw a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 1,690,000 shares, a drop of 12.0% from the November 30th total of 1,920,000 shares. Based on an average daily trading volume, of 354,200 shares, the short-interest ratio is currently 4.8 days.

AlloVir Price Performance

Shares of ALVR stock traded down $0.02 on Friday, reaching $0.46. 167,042 shares of the stock were exchanged, compared to its average volume of 589,223. The stock has a 50 day moving average price of $0.62 and a 200 day moving average price of $0.72. The stock has a market cap of $52.81 million, a PE ratio of -0.52 and a beta of 0.59. AlloVir has a one year low of $0.40 and a one year high of $1.05.

AlloVir (NASDAQ:ALVR) last released its earnings results on Tuesday, November 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10.

Hedge Funds Weigh In On AlloVir

An institutional investor recently raised its position in AlloVir stock. Cubist Systematic Strategies LLC raised its holdings in shares of AlloVir, Inc. (NASDAQ:ALVR) by 152.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 49,816 shares of the company’s stock after acquiring an additional 30,072 shares during the period. Cubist Systematic Strategies LLC’s holdings in AlloVir were worth $36,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 66.05% of the company’s stock.

AlloVir Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.